Drug Profile
Interferon alpha-n1 - Sumitomo Pharma
Alternative Names: IFN-α - Sumitomo Pharma ; Interferon-alfa - Sumitomo Pharma ; Interferon-α NAMALWA; SumiferonLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer Sumitomo Pharma
- Class Antineoplastics; Antivirals; Interferons
- Mechanism of Action Interferon alpha stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Liver cirrhosis